Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

30 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Sotrovimab therapy elicits antiviral activities against Omicron BQ.1.1 and XBB.1.5 in sera of immunocompromised patients.
Bruel T, Vrignaud LL, Porrot F, Staropoli I, Planas D, Guivel-Benhassine F, Puech J, Prot M, Munier S, Bolland WH, Soulié C, Zafilaza K, Lusivika-Nzinga C, Meledge ML, Dorival C, Molino D, Péré H, Yordanov Y, Simon-Lorière E, Veyer D, Carrat F, Schwartz O, Marcelin AG, Martin-Blondel G; ANRS 0003S CoCoPrev Study Group. Bruel T, et al. Among authors: lusivika nzinga c. Med. 2023 Oct 13;4(10):664-667. doi: 10.1016/j.medj.2023.07.007. Med. 2023. PMID: 37837962 Free article.
Sofosbuvir-Daclatasvir is suboptimal in patients with genotype 2 chronic hepatitis C infection: real-life experience from the HEPATHER ANRS CO22 cohort.
de Lédinghen V, Lusivika-Nzinga C, Bronowicki JP, Zoulim F, Larrey D, Metivier S, Tran A, Marcellin P, Samuel D, Chazouillères O, Chevaliez S, Dorival C, Fontaine H, Pawlotsky JM, Carrat F, Pol S; AFEF/ANRS Study Group. de Lédinghen V, et al. J Viral Hepat. 2020 Oct;27(10):964-973. doi: 10.1111/jvh.13321. Epub 2020 May 21. J Viral Hepat. 2020. PMID: 32436335 Free article.
Outcome of very high-risk patients treated by Sotrovimab for mild-to-moderate COVID-19 Omicron, a prospective cohort study (the ANRS 0003S COCOPREV study).
Martin-Blondel G, Marcelin AG, Soulié C, Kaisaridi S, Lusivika-Nzinga C, Dorival C, Nailler L, Boston A, Melenotte C, Gaube G, Choquet C, Liblau R, Carrat F, Yordanov Y; COCOPREV Study Group. Martin-Blondel G, et al. J Infect. 2022 Jun;84(6):e101-e104. doi: 10.1016/j.jinf.2022.04.010. Epub 2022 Apr 7. J Infect. 2022. PMID: 35398409 Free PMC article. No abstract available.
Prediction of hepatocellular carcinoma in Hepatitis C patients with advanced fibrosis after sustained virologic response.
Azzi J, Dorival C, Cagnot C, Fontaine H, Lusivika-Nzinga C, Leroy V, De Ledinghen V, Tran A, Zoulim F, Alric L, Gournay J, Bronowicki JP, Decaens T, Riachi G, Mikhail N, Soliman R, Shiha G, Pol S, Carrat F, Ganne-Carrié N; ANRS-AFEF Hepather Study group. Azzi J, et al. Clin Res Hepatol Gastroenterol. 2022 Jun-Jul;46(6):101923. doi: 10.1016/j.clinre.2022.101923. Epub 2022 Apr 9. Clin Res Hepatol Gastroenterol. 2022. PMID: 35405354 Free article.
Sotrovimab to prevent severe COVID-19 in high-risk patients infected with Omicron BA.2.
Martin-Blondel G, Marcelin AG, Soulié C, Kaisaridi S, Lusivika-Nzinga C, Dorival C, Nailler L, Boston A, Melenotte C, Cabié A, Choquet C, Coustillères F, Martellosio JP, Gaube G, Trinh-Duc A, Ronchetti AM, Pourcher V, Chauveau M, Lacombe K, Peiffer-Smadja N, Housset P, Perrot A, Pialoux G, Martin A, Dubee V, Devaux M, Frey J, Cazanave C, Liblau R, Carrat F, Yordanov Y. Martin-Blondel G, et al. J Infect. 2022 Oct;85(4):e104-e108. doi: 10.1016/j.jinf.2022.06.033. Epub 2022 Jul 5. J Infect. 2022. PMID: 35803386 Free PMC article. No abstract available.
Impact of direct-acting antiviral treatment for hepatitis C on cardiovascular diseases and extrahepatic cancers.
Lam L, Fontaine H, Lapidus N, Dorival C, Bellet J, Larrey D, Nahon P, Diallo A, Cagnot C, Lusivika-Nzinga C, Téoulé F, Hejblum G, Bourlière M, Pol S, Carrat F; ANRS/AFEF Hepather study group. Lam L, et al. Pharmacoepidemiol Drug Saf. 2023 Apr;32(4):486-495. doi: 10.1002/pds.5576. Epub 2022 Dec 5. Pharmacoepidemiol Drug Saf. 2023. PMID: 36444965
Performance of algorithms for identifying patients with chronic hepatitis B or C infection in the french health insurance claims databases using the ANRS CO22 HEPATHER cohort.
Lam L, Fontaine H, Lapidus N, Bellet J, Lusivika-Nzinga C, Nicol J, Dorival C, Cagnot C, Hejblum G, Pol S, Bourlière M, Carrat F; ANRS/AFEF HEPATHER Study Group. Lam L, et al. J Viral Hepat. 2023 Mar;30(3):232-241. doi: 10.1111/jvh.13788. Epub 2022 Dec 27. J Viral Hepat. 2023. PMID: 36529681
30 results